CG Oncology vs Relay Therapeutics
CGON and RLAY side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CGON and RLAY compare
CG Oncology is the larger company, worth 1.7 times as much as Relay Therapeutics ($6.6B against $4.0B).
CG Oncology grew revenue faster over the last twelve months (184% versus 23.9% for Relay Therapeutics).
Relay Therapeutics keeps more of each dollar of sales as profit, with a net margin of −2837% compared with −3851% at CG Oncology.
Relay Therapeutics scores higher on the StockData Score (10 against 5 for CG Oncology), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CGON | RLAY |
|---|---|---|
| Size and price | ||
| Market cap | $6.6B | $4.0B |
| Share price | $74.40 | $18.09 |
| Change, 1 year | 88.8% | 193% |
| Change, 5 years | – | −47.5% |
| Beta (5Y) | 1.40 | 1.94 |
| Employees | 142 | 192 |
| StockData Score | ||
| Total score | 5 | 10 (better) |
| Valuation score | 0 | 0 |
| Growth score | 1 | 2 (better) |
| Performance score | 1 | 2 (better) |
| Health score | 3 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 1070× | 383× (better) |
| P/B | 6.7× | 4.8× (better) |
| FCF yield | −2.9% | – |
| Growth | ||
| Revenue growth (TTM) | 184% (better) | 23.9% |
| Revenue growth, 5Y average | – | −28.6% |
| Profitability | ||
| Operating margin | −4294% | −3095% (better) |
| Net margin | −3851% | −2837% (better) |
| FCF margin | −3068% | – |
| Return on equity | −28.3% (better) | −41.2% |
| Return on invested capital | −2103% | −41.8% (better) |
| Financial health | ||
| Debt / equity | 0.00 (better) | 0.00 |
| Current ratio | 21.70 (better) | 14.62 |
| Altman Z-score | 70.54 (better) | 25.18 |
| Piotroski F-score | 1 | 4 (better) |
| Dividends and buybacks | ||
| Buyback yield | −7.4% | – |
| Shareholder yield | −7.4% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 106% | 113% |
| Held by insiders | 17.3% | 24.5% |
| Insider net buying, 12 months | $20.0M (better) | −$129M |
| Superinvestors holding | – | 1 |
| Short interest, % of float | 12.6% | 26.4% |
Go deeper
- CGON stock overview
- CGON income statement
- CGON valuation and score
- RLAY stock overview
- RLAY income statement
- RLAY valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.